Literature Citations
1. Novel Heterocyclic 1,3,4-oxadiazole Derivatives of Fluoroquinolones as a Potent Antibacterial Agent: Synthesis and Computational Molecular Modeling. Allaka, T.R., B. Kummari, N. Polkam, N. Kuntala, K. Chepuri, and J.S. Anireddy. Molecular Diversity, 2022. 26(3): p. 1581-1596. PMID[34341943].
[PubMed]. TB_06_2022.
2. Development of New Antimycobacterial Sulfonyl hydrazones and 4-Methyl-1,2,3-thiadiazole-based Hydrazone Derivatives. Angelova, V.T., T. Pencheva, N. Vassilev, E. K-Yovkova. E, R. Mihaylova, B. Petrov, and V. Valcheva. Antibiotics, 2022. 11(5). PMID[35625207]. PMCID[PMC9137698].
[PubMed]. TB_06_2022.
3. In Vitro Activity of Tedizolid and Linezolid against Multidrug-resistant Mycobacterium tuberculosis: A Comparative Study Using Microdilution Broth Assay and Genomics. Aono, A., Y. Murase, K. Chikamatsu, Y. Igarashi, Y. Shimomura, M. Hosoya, A. Osugi, Y. Morishige, A. Takaki, H. Yamada, and S. Mitarai. Diagnostic Microbiology and Infectious Disease, 2022. 103(3): 115714. PMID[35596983].
[PubMed]. TB_06_2022.
4. Identifying RO9021 as a Potential Inhibitor of PknG from Mycobacterium tuberculosis: Combinative Computational and in Vitro Studies. Arica-Sosa, A., R. Alcántara, G. Jiménez-Avalos, M. Zimic, P. Milón, and M. Quiliano. ACS Omega, 2022. 7(23): p. 20204-20218. PMID[35721990]. PMCID[PMC9201901].
[PubMed]. TB_06_2022.
5. Synthesis and in Vitro Studies for Structure-based Design of Novel Chalcones as Antitubercular Agents Targeting InhA. Dhivya, L.S., B.R. Pradeepa, and S. Sarvesh. Future Medicinal Chemistry, 2022. 14(12): p. 851-866. PMID[35548879].
[PubMed]. TB_06_2022.
6. Potent Bactericidal Antimycobacterials Targeting the Chaperone ClpC1 Based on the Depsipeptide Natural Products Ecumicin and Ohmyungsamycin A. Hawkins, P.M.E., D.M. Hoi, C.Y. Cheung, T. Wang, D. Quan, V.M. Sasi, D.Y. Liu, R.G. Linington, C.J. Jackson, S.H. Oehlers, G.M. Cook, W.J. Britton, T. Clausen, and R.J. Payne. Journal of Medicinal Chemistry, 2022. 65(6): p. 4893-4908. PMID[35293761].
[PubMed]. TB_06_2022.
7. Synthesis, Optical Properties, Preliminary Antimycobacterial Evaluation and Docking Studies of Trifluoroacetylated 3-pyrrolyl boron-dipyrromethene. Horetski, M., A. Gorlova, A. Brzostek, Y. Faletrov, V. Shkumatov, R. Plociriska, and J. Dziadek. ChemistrySelect, 2022. 7(22): 100273. ISI[000808242200001].
[WOS]. TB_06_2022.
8. Improving Antimicrobial Activity and Physico-chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. Juhás, M., A. Bachtíková, D.E. Nawrot, P. Hatoková, V.S.K. Pallabothula, A. Diepoltová, O. Janďourek, P. Bárta, K. Konečná, P. Paterová, V. Šesták, and J. Zitko. Pharmaceuticals, 2022. 15(5): 580. PMID[35631406]. PMCID[PMC9143880].
[PubMed]. TB_06_2022.
9. Antitubercular Activity Assessment of Fluorinated Chalcones, 2-Aminopyridine-3-carbonitrile and 2-amino-4H-pyran-3-carbonitrile Derivatives: In Vitro, Molecular Docking and in-Silico Drug Likeliness Studies. Lagu, S.B., R.P. Yejella, S. Nissankararao, R.R. Bhandare, V.S. Golla, B.V. Subrahmanya Lokesh, M.M. Rahman, and A.B. Shaik. Plos One, 2022. 17(6): e0265068. PMID[35709194]. PMCID[PMC9202851].
[PubMed]. TB_06_2022.
10. Antimycobacterial Activity of Achyrocline flaccida (Asteraceae) Aqueous Extract from Southern Brazil. Machado, V.S., C.M. Verdi, G.G. Rossi, L.I. Souza, C.A. Teixeira, M.L. Machado, T.L. da Silveira, M.R. Sagrillo, A.K. Machado, R.C. Dornelles, M.M. Campos, E. Rodrigues, T. Emanuelli, S. Somacal, and R.C.V. Santos. Natural Product Research, 2022. 36(11): p. 2897-2901. PMID[34039226].
[PubMed]. TB_06_2022.
11. Design, Synthesis and Biological Evaluation of Novel Isoniazid Hybrids. Nalini, R., S.M. Basavarajaiah, G.Y. Nagesh, and K.R. Reddy. Journal of the Indian Chemical Society, 2022. 99(1): 100273. ISI[000795936800007].
[WOS]. TB_06_2022.
12. GSK2556286 Is a Novel Antitubercular Drug Candidate Effective in Vivo with the Potential to Shorten Tuberculosis Treatment. Nuermberger, E.L., M.S. Martínez-Martínez, O. Sanz, B. Urones, J. Esquivias, H. Soni, R. Tasneen, S. Tyagi, S.Y. Li, P.J. Converse, H.I. Boshoff, G.T. Robertson, G.S. Besra, K.A. Abrahams, A.M. Upton, K. Mdluli, G.W. Boyle, S. Turner, N. Fotouhi, N.C. Cammack, J.M. Siles, M. Alonso, J. Escribano, J. Lelievre, J. Rullas-Trincado, E. Pérez-Herrán, R.H. Bates, G. Maher-Edwards, D. Barros, L. Ballell, and E. Jiménez. Antimicrobial Agents and Chemotherapy, 2022. 66(6): e0013222. PMID[35607978]. PMCID[PMC9211396].
[PubMed]. TB_06_2022.
13. In Vitro Activity of Fidaxomicin against Nontuberculosis Mycobacteria. Sun, Q., X. Liao, C. Wang, G. Jiang, J. Yang, J. Zhao, H. Huang, G. Wang, and H. Li. Journal of Medical Microbiology, 2022. 71(6): 1549. PMID[35708979].
[PubMed]. TB_06_2022.
14. Antimicrobial Activities of Salacia oblonga Wall Leaf and Root Extracts against Different Bacterial Strains and Fungal Isolates. Surekha, C., R. Srikanth, M.K. Thupurani, N.R.R. Neelapu, and V. Peddireddy. Current Microbiology, 2022. 79(7): 204. PMID[35612657].
[WOS]. TB_06_2022.
15. Evaluation of a Novel Inhibitor of Aspartate semialdehyde dehydrogenase as a Potent Antitubercular Agent against Mycobacterium tuberculosis. Yang, R., W. Cao, S. Liu, Q. Li, Y. Sun, C. Liang, W. Ren, Y. Liu, J. Meng, and C. Li. The Journal of Antibiotics, 2022. 75(6): p. 333-340. PMID[35422103].
[PubMed]. TB_06_2022.
16. 5-Aminolevulinic acid-photodynamic Therapy Ameliorates Cutaneous Granuloma by Killing Drug-resistant Mycobacterium marinum. Yang, Z., Y. Feng, D. Li, Z. Pang, S. Wang, H. Chen, M. Jiang, H. Yan, T. Li, H. Fu, H. Xiong, and D. Shi. Photodiagnosis and Photodynamic Therapy, 2022. 38: 102839. PMID[35367615].
[PubMed]. TB_06_2022.
17. Design, Synthesis and anti-Mycobacterium tuberculosis Evaluation of New Thiazolidin-4-one and Thiazolo[3,2-a][1,3,5]triazine Derivatives. Younis, M.H., E.R. Mohammed, A.R. Mohamed, M.M. Abdel-Aziz, H.H. Georgey, and N.M. Abdel Gawad. Bioorganic Chemistry, 2022. 124: 105807. PMID[35487073].
[PubMed]. TB_06_2022.
Patent Citations
18. A Medicament for Treating Mycobacterial Infection Characterized by Combining a Cytochrome BC1 Inhibitor with Clarithromycin or Azithromycin. Nishiguchi, K., Y. Yoshioka, S. Hirukawa, T. Hara, W.D. Claypool, M.J. Miller, G.C. Moraski, and J.S. Schorey. Patent. 2022. 2021-WO2022119899A1: 146pp.
[Patent]. TB_06_2022.